阿扎胞苷联合CAG方案治疗复发难治急性髓系白血病临床效果分析  

Analysis of clinical effect of azacitidine combined with CAG regimen on treatment of relapsed/refractory acute myeloid leukemia

作　　者：王共爱 薛克伟 李淑美[1] 郝云良[1] 董沙沙 Wang Gongai;Xue Kewei;Li Shumei;Hao Yunliang;Dong Shasha(Department of Hematology,Jining No.1 People's Hospital,Jining 272100,China;Department of Oncology,Jining No.1 People's Hospital,Jining 272100,China)

机构地区：[1]山东省济宁市第一人民医院血液内科,272100 [2]山东省济宁市第一人民医院肿瘤科,272100

出　　处：《白血病．淋巴瘤》2020年第3期157-159,共3页Journal of Leukemia & Lymphoma

摘　　要：目的探讨阿扎胞苷联合CAG方案治疗复发难治急性髓系白血病(AML)的临床疗效。方法回顾性分析2018年9月至2019年9月济宁市第一人民医院50例复发难治AML(非急性早幼粒细胞白血病)患者资料,根据不同用药方法分为对照组和试验组。对照组(28例)单用CAG方案治疗,试验组(22例)采用阿扎胞苷联合CAG方案治疗,治疗1个疗程后观察两组的有效率及不良反应。结果治疗1个疗程后,试验组临床总有效率为86%(19/22),对照组总有效率为71%(20/28),两组间比较差异有统计学意义(χ^2=5.273,P<0.05)。两组患者的发热、肺部感染、呕吐、血小板减少等不良反应发生率差异均无统计学意义(均P>0.05)。结论阿扎胞苷联合CAG方案治疗复发难治AML可提高临床疗效,且不增加患者的不良反应。Objective To explore the clinical effect of azacitidine combined with CAG regimen on the treatment of relapsed/refractory acute myeloid leukemia(AML).Methods The data of 50 patients with relapsed/refractory AML(non-acute promyelocytic leukemia)in Jining No.1 People's Hospital from September 2018 to September 2019 was retrospectively analyzed,and the patients were divided into the control group and the test group according to the different treatment drugs.The control group(28 cases)was treated with CAG regimen alone,and the test group(22 cases)was treated with azacitidine combined with CAG regimen.The total effective rate and adverse reactions of the two groups were observed after 1 course of treatment.Results After one course of treatment,the total clinical effective rate in the test group was 86%(19/22),and the rate in the control group was 71%(20/28),there was a statistically significant difference between the two groups(χ^2=5.273,P<0.05).There were no significant differences in the incidence of adverse reactions such as fever,pulmonary infection,vomiting,and thrombocytopenia between the two groups(all P>0.05).Conclusion Azacitidine combined with CAG regimen in the treatment of relapsed/refractory AML can improve the clinical efficacy without increasing the adverse reactions.

关 键 词：白血病 髓样 急性 复发 难治 阿扎胞苷 CAG方案 

分 类 号：R733[医药卫生—肿瘤]